公开(公告)号：US20200247784A1

公开(公告)日：2020-08-06

申请号：US16774786

申请日：2020-01-28

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  C07D413/12 ,  A61P35/00

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US10662204B2

公开(公告)日：2020-05-26

申请号：US16263185

申请日：2019-01-31

Applicant: PFIZER INC.

Inventor： Simon Planken ,  Hengmiao Cheng ,  Michael Raymond Collins ,  Jillian Elyse Spangler ,  Alexei Brooun ,  Andreas Maderna ,  Cynthia Palmer ,  Maria Angelica Linton ,  Asako Nagata ,  Ping Chen

IPC: C07D403/12 ,  C07D403/14 ,  C07D407/14 ,  C07D487/10 ,  A61P35/00 ,  C07D519/00 ,  C07D471/04 ,  C07D487/04 ,  C07D417/14 ,  C07D413/14 ,  A61P25/00

Abstract: Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and administration of these compounds to patients to treat pancreatic, lung, colon and other cancers.

公开(公告)号：US10590115B2

公开(公告)日：2020-03-17

申请号：US16265012

申请日：2019-02-01

Applicant: PFIZER INC.

Inventor： Simon Planken ,  Hengmiao Cheng ,  Michael Raymond Collins ,  Jillian Elyse Spangler ,  Alexei Brooun ,  Andreas Maderna ,  Cynthia Palmer ,  Maria Angelica Linton ,  Asako Nagata ,  Ping Chen

IPC: C07D403/14 ,  C07D487/10 ,  A61P35/00 ,  C07D403/04 ,  C07D239/94

Abstract: Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

公开(公告)号：US11718603B2

公开(公告)日：2023-08-08

申请号：US17235836

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

CPC classification number: C07D403/12 ,  A61P35/00 ,  C07D413/12 ,  C07B2200/07

Abstract: This invention relates to compounds of Formula (I)




and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20220324872A1

公开(公告)日：2022-10-13

申请号：US17841138

申请日：2022-06-15

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Ping Chen ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Mehran Jalaie ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Martha Alicia Ornelas ,  Cynthia Louise Palmer ,  Eugene Yuanjin Rui

IPC: C07D487/04 ,  C07D471/04 ,  C07D401/14

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20210269425A1

公开(公告)日：2021-09-02

申请号：US17235846

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20190135817A1

公开(公告)日：2019-05-09

申请号：US16251032

申请日：2019-01-17

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Ping Chen ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Mehran Jalaie ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Martha Alicia Ornelas ,  Cynthia Louise Palmer ,  Eugene Yuanjin Rui

IPC: C07D487/04 ,  C07D401/14 ,  C07D471/04

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2 , R2A , R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US10233188B2

公开(公告)日：2019-03-19

申请号：US15664265

申请日：2017-07-31

Applicant: Pfizer Inc.

Inventor： Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic

IPC: A61K31/519 ,  A61K31/4375 ,  A61K31/4545 ,  C07D487/04 ,  C07D401/12 ,  C07D401/14 ,  C07D471/04

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20150141402A1

公开(公告)日：2015-05-21

申请号：US14548749

申请日：2014-11-20

Applicant: PFIZER INC.

Inventor： Douglas Carl Behenna ,  Hengmiao Cheng ,  Sujin Cho-Schultz ,  Theodore Otto Johnson, JR. ,  John Charles Kath ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Simon Paul Planken

IPC: C07D473/16

CPC classification number: C07D473/16 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/5386 ,  C07D473/18 ,  C07D519/00

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中Q，G，环A，环B，R1，R2，R3，R4，R5，R5a，R6，R7，R8，R9， R 11，R 12，R 13，R 14，R 15，R 16，R 17，R 18，R 19，R 20，R 21，R 22，R 23，R 24和m如本文所定义。 新型嘌呤衍生物可用于治疗哺乳动物中异常细胞生长，如癌症。 另外的实施方案涉及含有化合物的药物组合物和使用化合物和组合物治疗哺乳动物异常细胞生长的方法。